Why Is CSL (ASX:CSL) Launching Its New Flu Vaccine First In The UK?
CSL has secured a multi-year agreement with the UK government to launch its adjuvanted, trivalent cell-based flu vaccine, Aujemflu. This move leverages CSL's existing UK manufacturing infrastructure to support pandemic preparedness and long-term revenue growth.
Why it matters
The deal signals a strategic shift for CSL toward recurring, high-margin government contracts, which is critical for the company's financial recovery and operational transformation.
Why Is CSL (ASX:CSL) Launching Its New Flu Vaccine First In The UK? Bailey Pemberton Tue, September 22, 2026 at 8:18 PM EDT 2 min read CSL.AX -0.82% CSL (ASX:CSL) has secured a multi-year Advance Purchase Agreement extension with the UK government for its Aujemflu vaccine.
The UK will be the first country to commercially launch CSL Seqirus' adjuvanted, trivalent cell-based influenza vaccine Aujemflu.
The agreement highlights the role of CSL's UK manufacturing hub in supporting national pandemic preparedness and large-scale flu vaccine supply.
The Aujemflu launch and UK purchase extension only capture part of what this move could mean for CSL's wider vaccine position. Take a look at 1 warning sign we have identified for CSL.
Explore other vaccine and broader healthcare stocks that could benefit from similar government partnerships and long-term supply agreements through our screener containing 16 high quality undiscovered gems .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in